Physician profile
Robert Kent Chiang
NPI 1306849526
$3,060.64
in general payments reported to CMS, 2019-2025
17 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $292 · 2021: $229 · 2022: $592 · 2023: $402 · 2024: $523 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,276.93 | 2019-2025 | Tecnis Iol, Catalys System, Healon Duet Pro |
| Alcon Vision LLC | $303.51 | 2019-2025 | Clareon, Rocklatan |
| Allergan, INC. | $279.21 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $240.47 | 2022-2024 | Vyzulta, Lotemax Sm, Prolensa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $155.63 | 2019-2021 | |
| Abbvie INC. | $148.59 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Astellas Pharma US INC | $124.87 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $124.01 | 2025 | Xdemvy |
| Glaukos Corporation | $110.80 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Novartis Pharmaceuticals Corporation | $69.43 | 2019-2023 | |
| New World Medical,INC. | $60.05 | 2024-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Kala Pharmaceuticals, INC. | $49.24 | 2019-2020 | |
| Ocular Therapeutix, INC. | $32.97 | 2020-2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $29.24 | 2019-2021 | |
| Harrow Eye, LLC | $25.00 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $17.79 | 2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.